泰瓦索DPI:药物设备特征和患者临床考虑
Colleen McEvoy1, Rahul Argula2, Sandeep Sahay3
1Division of Pulmonary and Critical Care Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Pulmonary pharmacology & therapeutics
|November 15, 2023
概括
泰瓦索DPI提供了一种方便的,呼吸驱动的干粉吸入器,用于特雷布罗斯尼,改善了肺高血压的治疗. 这种便携式设备确保了有针对性的分娩和高患者满意度,提高了坚持.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 医疗器械 医疗器械
背景情况:
- 肺动脉高血压 (PAH) 和与间歇性肺病 (PH-ILD) 相关的肺高血压需要有效的治疗选择.
- prostinil是一种用于治疗这些疾病的前环素类似物.
- 现有的输送方法,如雾化器,在便携性和患者坚持性方面可能会带来挑战.
研究的目的:
- 评估Tyvaso干粉吸入器 (DPI) 作为一种新的药物-设备联合疗法,用于特雷沙的输送.
- 为了比较Tyvaso DPI与 nebulized treprostinil溶液的疗效,安全性和患者满意度.
- 探索Tyvaso DPI在各种患者群体和治疗场景中的潜在益处.
主要方法:
- 泰瓦索DPI是一款采用气息驱动的干粉吸入器,使用含有特雷普罗斯尼尔微粒的一次性使用弹.
- 该设备是为被动管理而设计的,不需要与吸入器进行协调.
- 一项临床研究将Tyvaso DPI与肺动脉高血压患者的雾化特雷布罗斯尼溶液进行比较.
主要成果:
- 与雾化溶液相比,Tyvaso DPI表现出类似的特雷普罗斯尼暴露和药理动力学.
- 对于Tyvaso DPI,不良事件的发生率很低.
- 患者对Tyvaso DPI设备表示高度满意,理由是其便携性和易于使用.
结论:
- 泰瓦索DPI是治疗PAH和PH-ILD的有效和耐受良好的选择.
- 它的设计有助于有针对性地向外围肺部输送,从而最大限度地减少口腔脉冲击.
- 泰瓦索DPI为患者提供了一个患者喜欢的,便携式的,并可能改善粘附的替代方案,用于 nebulized prostacyclin 治疗,适合活跃的患者和那些患有并发症.
相关概念视频
01:23Inhaled Medications
284
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
284
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
162
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
162
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
176
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
176
01:28Special considerations while measuring blood pressure
727
When assessing blood pressure (BP), healthcare professionals must consider various factors and potential unexpected outcomes to ensure accurate readings and provide proper patient care. Adhering to these guidelines is essential to achieving the most reliable results.
Monitoring Both Arms:
Monitoring BP in both arms during the initial assessment is advisable, as the systolic value may differ by five to ten mm Hg between arms. For subsequent BP assessments, use the arm with the higher reading.
Monitoring Both Arms:
Monitoring BP in both arms during the initial assessment is advisable, as the systolic value may differ by five to ten mm Hg between arms. For subsequent BP assessments, use the arm with the higher reading.
727
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
171
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
171